These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30288049)

  • 1. Distribution of CD4
    Shi F; Chang H; Zhou Q; Zhao YJ; Wu GJ; Song QK
    Onco Targets Ther; 2018; 11():6139-6145. PubMed ID: 30288049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell Counts, rather than Proportion, of CD8/PD-1 Tumor-Infiltrating Lymphocytes in a Tumor Microenvironment Associated with Pathological Characteristics of Chinese Invasive Ductal Breast Cancer.
    Song Q; Shi F; Adair M; Chang H; Guan X; Zhao Y; Li Y; Wu G; Wu J
    J Immunol Res; 2019; 2019():8505021. PubMed ID: 31049361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
    Wang RB; Li YC; Zhou Q; Lv SZ; Yuan KY; Wu JP; Zhao YJ; Song QK; Zhu B
    World J Clin Cases; 2020 Dec; 8(23):5935-5943. PubMed ID: 33344592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer.
    Alkhayyal N; Elemam NM; Hussein A; Magdub S; Jundi M; Maghazachi AA; Talaat IM; Bendardaf R
    Heliyon; 2022 Sep; 8(9):e10482. PubMed ID: 36097493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
    BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
    Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
    Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
    Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
    PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer.
    Hayashi K; Nogawa D; Kobayashi M; Asakawa A; Ohata Y; Kitagawa S; Kubota K; Takahashi H; Yamada M; Oda G; Nakagawa T; Uetake H; Onishi I; Kinowaki Y; Kurata M; Kitagawa M; Yamamoto K
    Front Oncol; 2022; 12():901591. PubMed ID: 36132149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of E-cadherin and Ki-67 associated with functional/dysfunctional phenotypes of tumor-infiltrating lymphocytes among Chinese patients with operable breast cancer.
    Wang R; Shi F; Zhao L; Zhao Y; Wu G; Song QK
    J Int Med Res; 2018 Dec; 46(12):5219-5227. PubMed ID: 30318965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.